We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Effects of Nano-curcumin Supplementation on Serum Level of hs-CRP, Adhesion Molecules, and Lipid Profiles in Hemodialysis Patients, A Randomized Controlled Clinical Trial.
- Authors
Vafadar Afshar, Golchin; Rasmi, Yousef; Yagmayee, Parichehreh; Khadem-Ansari, Mohammad-Hasan; Makhdomii, Khadijeh; Rasooli, Javad; Yaghmaei, Parichehreh
- Abstract
<bold>Introduction: </bold>Hemodialysis (HD) patients are considered as a high-risk population for cardiovascular disease, within which morbidity and mortality have been determined to be associated with dyslipidemia, pro-inflammatory cytokines, increased levels of C-reactive protein (CRP), and adhesion molecules (ICAM-1, VCAM-1). Different markers have been investigated to detect inflammation in hemodialysis patients, as well as the prognostic values of these markers.<bold>Methods: </bold>The present study aimed to investigate the effect of nano-curcumin (120 mg) over 12 weeks on hs-CRP levels, adhesion molecules (ICAM-1, VCAM-1), and serum lipid profiles on hemodialysis patients in a randomized controlled clinical trial.<bold>Results: </bold>The results revealed that the mean serum hs-CRP level in the nano-curcumin group exhibited a decrease by the end of the study, when compared to mean serum hs-CRP level in the placebo group. However, this between-group trend was not found to be statistically significant (P > .05). Nevertheless, a significant difference was determined between the values in the group receiving nano-curcumin, in comparison with the placebo group, at the end of the study (P < .001). Based on the attained results, mean serum levels of VCAM-1 in the nano-curcumin group were significantly reduced at the end of the study, compared with the placebo group (P < .001). Furthermore, the between-group changes comparison showed significant reductions in serum levels of ICAM- 1 in patients treated with nano-curcumin at the end of the study (P < .05). Additionally, though decreases in mean triglycerides, total cholesterol, LDL-C were noted, there were no statistically significant between-group differences (P > .05). Moreover, between-group changes comparison of HDL-C levels and fasting blood sugar did not show any significant changes.<bold>Conclusion: </bold>The current study indicates that nano-curcumin may show beneficial effects in lowering inflammation and hs-CRP levels, as well as adhesion molecules (ICAM-1, VCAM-1), in hemodialysis patients. However, the evidence is still insufficient.
- Subjects
C-reactive protein; RESEARCH; HERBAL medicine; BIOLOGICAL products; INFLAMMATION; MULTIVARIATE analysis; RESEARCH methodology; CURCUMIN; CARDIOVASCULAR diseases; REGRESSION analysis; EVALUATION research; MEDICAL cooperation; COMPARATIVE studies; RANDOMIZED controlled trials; BLIND experiment; HEMODIALYSIS; ANTIGENS; LIPIDS
- Publication
Iranian Journal of Kidney Diseases, 2020, Vol 14, Issue 1, p52
- ISSN
1735-8582
- Publication type
journal article